Transdermal Scopolamine Market Is Projected to Reach US $585.3 Mn by 2024
A new study by Transparency Market Research (TMR) indicates that Novartis AG, alone, contributed nearly 41.0% of the overall revenue of the global transdermal scopolamine market in 2016. Other two torch bearers in the market, namely, GlaxoSmithKline Plc and Baxter International Inc., commanded a cumulative share of 49.0% in the same year. Even though, the number of small players in the market is less, the degree of competition within the arena will remain low over the forthcoming years. "The leading...
View full press release